Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Paliperidone Palmitate in Schizophrenia
NCT01606254Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2007
- Primary completion
- Apr 2008
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Jan 2007; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01606254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01606254.